Walker Samuel N, Lucas Kilean, Dewey Marley J, Badylak Stephen F, Hussey George S, Flax Jonathan, McGrath James L
Department of Biomedical Engineering, University of Rochester, Rochester, NY, 14627, USA.
McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, 15219, USA.
Small. 2024 Oct 2:e2405505. doi: 10.1002/smll.202405505.
Extracellular vesicles (EVs) are particles released from cells that facilitate intercellular communication and have tremendous diagnostic and therapeutic potential. Bulk assays lack the sensitivity to detect rare EV subsets relevant to disease, and while single EV analysis techniques remedy this, they are often undermined by complicated detection schemes and prohibitive instrumentation. To address these issues, a microfluidic technique for EV characterization called "catch and display for liquid biopsy (CAD-LB)" is proposed. In this method, minimally processed samples are pipette-injected and fluorescently labeled EVs are captured in the nanopores of an ultrathin membrane. This enables the rapid assessment of EV number and biomarker colocalization by light microscopy. Here, nanoparticles are used to define the accuracy and dynamic range for counting and colocalization. The same assessments are then made for purified EVs and for unpurified EVs in plasma. Biomarker detection is validated using CD9 and Western blot analysis to confirm that CAD-LB accurately reports relative protein expression levels. Using unprocessed conditioned media, CAD-LB captures the known increase in EV-associated ICAM-1 following endothelial cell cytokine stimulation. Finally, to demonstrate CAD-LB's clinical potential, EV biomarkers indicative of immunotherapy responsiveness are successfully detected in the plasma of bladder cancer patients treated with immune checkpoint blockade.
细胞外囊泡(EVs)是从细胞释放的颗粒,有助于细胞间通讯,具有巨大的诊断和治疗潜力。大量分析缺乏检测与疾病相关的罕见EV亚群的灵敏度,虽然单一EV分析技术弥补了这一不足,但它们常常因复杂的检测方案和昂贵的仪器而受到影响。为了解决这些问题,提出了一种用于EV表征的微流控技术,称为“液体活检捕获与显示(CAD-LB)”。在该方法中,将最少处理的样品用移液器注入,荧光标记的EVs被捕获在超薄膜的纳米孔中。这使得能够通过光学显微镜快速评估EV数量和生物标志物共定位。在这里,使用纳米颗粒来定义计数和共定位的准确性和动态范围。然后对纯化的EVs和血浆中的未纯化EVs进行相同的评估。使用CD9和蛋白质印迹分析验证生物标志物检测,以确认CAD-LB准确报告相对蛋白质表达水平。使用未处理的条件培养基,CAD-LB捕获内皮细胞细胞因子刺激后EV相关ICAM-1的已知增加。最后,为了证明CAD-LB的临床潜力,在接受免疫检查点阻断治疗的膀胱癌患者的血浆中成功检测到指示免疫治疗反应性的EV生物标志物。